Histogenics Corp (NASDAQ:HSGX)’s share price dropped 28.6% on Wednesday . The stock traded as low as $2.70 and last traded at $0.90. Approximately 174,413 shares traded hands during trading, a decline of 28% from the average daily volume of 242,259 shares. The stock had previously closed at $0.70.
HSGX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $3.50 target price on shares of Histogenics in a report on Monday, August 13th. Brookline Cap M restated a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. Zacks Investment Research upgraded Histogenics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Thursday, July 12th. Finally, ValuEngine upgraded Histogenics from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Histogenics presently has a consensus rating of “Buy” and a consensus price target of $2.92.
The stock has a market cap of $85.37 million, a PE ratio of -0.84 and a beta of 1.69.
Histogenics (NASDAQ:HSGX) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.10. research analysts forecast that Histogenics Corp will post -0.71 EPS for the current fiscal year.
Several large investors have recently modified their holdings of the company. DRW Securities LLC acquired a new stake in shares of Histogenics in the second quarter valued at about $242,000. Renaissance Technologies LLC grew its position in shares of Histogenics by 6.1% in the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 22,133 shares during the last quarter. BlackRock Inc. grew its position in shares of Histogenics by 72.0% in the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 22,927 shares during the last quarter. Sofinnova Ventures Inc acquired a new stake in shares of Histogenics in the first quarter valued at about $5,712,000. Finally, Archon Capital Management LLC acquired a new stake in shares of Histogenics in the first quarter valued at about $639,000. 45.89% of the stock is currently owned by institutional investors.
Histogenics Company Profile (NASDAQ:HSGX)
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Further Reading: Market Capitalization in the Stock Market
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.